Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products

Handbook of Health Economics

Volumn 2, Issue , 2011, Pages 825-872

  Goldman, Dana ^a   Lakdawalla, Darius ^a  

^a NONE

Author keywords

Innovation; Medical devices; Patents; Pharmaceuticals

Indexed keywords

EID: 83255174931     PISSN: 15740064     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53592-4.00013-X     Document Type: Chapter

References (122)

1. Acemoglu D., Linn J. Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 2004, 119(3):1049-1090.
2. Albainy-Jenei S. Claim construction and the doctrine of equivalents in Amgen v Transkaryotic Therapies, Inc. Journal of Intellectual Property Law Practice 2006, 1(13):819-821.
3. Arora A., Ceccagnoli M., Cohen W.M. R&D and the patent premium. International Journal of Industrial Organization 2008, 26(5):1153-1179.
4. Berndt, E., et al. (2004). Did the Prescription Drug Use Fee Act affect the FDA approval process? In Frontiers in Health Policy Research. Chicago: University of Chicago Press.
5. Berndt E.R. Pharmaceuticals in U.S. health care: Determinants of quantity and price. Journal of Economic Perspectives 2002, 16(4):45-66.
6. Berndt E.R., et al. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 1995, 85(2):100-105.
7. Berndt E.R., et al. An analysis of the diffusion of new antidepressants: Variety, quality, and marketing efforts. Journal of Mental Health Policy and Economics 2002, 5(1):3-19.
8. Bhagat S., Welch I. Corporate research & development investments: international comparisons. Journal of Accounting and Economics 1995, 19(2-3):443-470.
9. Bhattacharya J., Vogt W.B. A simple model of pharmaceutical price dynamics. Journal of Law and Economics 2003, 46(2):599-626.
10. Bhattacharya S., Glazer J., Sappington D.E.M. Licensing and the sharing of knowledge in research joint ventures. Journal of Economic Theory 1992, 56(1):43-69.
11. Blume-Kohout, M. (2009). Drug development and public research funding: Evidence of lagged effects, RAND.
12. Blume-Kohout M., Sood N. Medicare Part D and pharmaceutical R&D 2009, RAND Corporation, Santa Monica, CA, (RAND Corporation Working Paper).
13. Blume-Kohout M.E., Kumar K.B., Sood N. Federal life sciences funding and university R&D 2009, National Bureau of Economic Research, Cambridge, MA, (National Bureau of Economic Research Working Paper 15146).
14. Boldrin M., Levine D.K. 2003 Lawrence R. Klein Lecture: The case against intellectual monopoly. International Economic Review 2004, 45(2):327-350.
15. Boldrin M., Levine D.K. Against intellectual monopoly 2008, Cambridge University Press, Cambridge and New York.
16. Brekke K.R., Grasdal A.L., Holmas T.H. Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?. European Economic Review 2009, 53(2):170-185.
17. Caves R.E., Whinston M.D., Hurwitz M.A. Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity 1991, 1-48.
18. Chang H.F. Patent scope, antitrust policy, and cumulative innovation. RAND Journal of Economics 1995, 26(1):34-57.
19. Clausen T.H. Do subsidies have positive impacts on R&D and innovation activities at the firm level?. Structural Change and Economic Dynamics 2009, 20(4):239-253.
20. Claxton K., et al. Value based pricing for NHS drugs: An opportunity not to be missed?. BMJ 2008, 336(7638):251-254.
21. Cohen, W. M., Nelson, R. R., & Walsh, J. P. (2000). Protecting their intellectual assets: appropriability conditions and why U.S. manufacturing firms patent (or not). National Bureau of Economic Research Working Paper Series No. 7552.
22. Comanor W.S. The political economy of the pharmaceutical industry. Journal of Economic Literature 1986, 24:1178-1217.
23. Congressional Budget Office How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry 1998, Congressional Budget Office, Washington, DC.
24. Crew M.A. Coinsurance and the welfare economics of medical care. American Economic Review 1969, 59(5):906-908.
25. Danzon P.M., Chao L. Does regulation drive out competition in pharmaceutical markets?. Journal of Law and Economics 2000, 43(2):311-357.
26. Danzon P.M., Pauly M.V. Insurance and new technology: From hospital to drugstore. Health Affairs 2001, 20(5):86-100.
27. Davidson M., et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. American Journal of Cardiology 1997, 79(11):1475-1481.
28. DiMasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: Is biotech different?. Managerial and Decision Economics 2007, 28(4-5):469-479.
29. Duggan M., Scott Morton F. The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review 2010, 100(1):590-607.
30. Ekelund M., Persson B. Pharmaceutical pricing in a regulated market. Review of Economics and Statistics 2003, 85(2):298-306.
31. Ellison, G. & Ellison, S. F. (2007). Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. National Bureau of Economic Research Working Paper Series No. 13069.
32. Encaoua D., Guellec D., Martinez C. Patent systems for encouraging innovation: Lessons from economic analysis. Research Policy 2006, 35(9):1423-1440.
33. Finkelstein A. Static and dynamic effects of health policy: Evidence from the vaccine industry. Quarterly Journal of Economics 2004, 119(2):527-564.
34. Folland S., Goodman A.C., Stano M. The economics of health and health care 2001, Prentice Hall, Upper Saddle River, NJ. 3rd ed.
35. Frech H.E. Competition and monopoly in medical care 1996, AEI Press, Washington.
36. Gallini N. Patent policy and costly imitation. RAND Journal of Economics 1992, 23:52-63.
37. Gans J.S., Hsu D.H., Stern S. The impact of uncertain intellectual property rights on the market for ideas: Evidence from patent grant delays. Management Science 2008, 54(5):982-997.
38. Garber A., Jones C., Romer P. Insurance and incentives for medical innovation. Forum for Health Economics and Policy 2006, 9(2). (Article 4).
39. Garrison L.P., Austin M.J.F. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs 2006, 25(5):1281-1290.
40. Gaynor M., Haas-Wilson D., Vogt W.B. Are invisible hands good hands? Moral hazard, competition, and the second-best in health care markets. Journal of Political Economy 2000, 108(5):992-1005.
41. Geoffard P.-Y., Philipson T. Disease eradication: Private versus public vaccination. American Economic Review 1997, 87(1):222-230.
42. Giaccotto C., Santerre R.E., Vernon J.A. Drug prices and research and development investment behavior in the pharmaceutical industry. Journal of Law and Economics 2005, 48(1):195-214.
43. Gilbert R., Shapiro C. Optimal patent length and breadth. RAND Journal of Economics 1990, 21:106-112.
44. Goldman D., et al. Valuing health technologies at NICE: Recommendations for improved incorporation of treatment value in HTA. Health Economics 2010, 19(10):1109-1116.
45. Goldman D.P., et al. The benefits from giving makers of conventional "small molecule" drugs longer exclusivity over clinical trial data. Health Affairs 2011, 30(1):84-90.
46. Grabowski H. The determinants of industrial research and development: A study of the chemical, drug and petroleum industries. Journal of Political Economy 1968, 7(6):292-306.
47. Grabowski, H. (2002). Patents and new product development in the pharmaceutical and biotechnology industries. Science and Cents: Exploring the Economics of Biotechnology Conference.
48. Grabowski H. Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nature Reviews Drug Discovery 2008, 7(6):479-488.
49. Grabowski H., Vernon J. The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics 2000, 10(1-2):201-215.
50. Green J.R., Scotchmer S. On the division of profit in sequential innovation. RAND Journal of Economics 1995, 26(1):20-33.
51. Gutman, S. (2004). Regulation of medical devices. Accessed: December 30, 2010.
52. Handbook of the economics of innovation 2011, Elsevier-North Holland, Amsterdam. B.H. Hall, J. Lerner (Eds.).
53. Harris C., Vickers J. Patent races and the persistence of monopoly. Journal of Industrial Economics 1985, 33(4):461-481.
54. Hicks J. The theory of wages 1932, Macmillan, London.
55. Hubbard R.G. Capital-market imperfections and investment. Journal of Economic Literature 1998, 36(1):193-225.
56. Hubbard T., Love J. A new trade framework for global healthcare R&D. PLoS Biology 2004, 2(2).
57. Iizuka T., Jin G.Z. The effect of prescription drug advertising on doctor visits. Journal of Economics and Management Strategy 2005, 14(3):701-727.
58. Iizuka T., Jin G.Z. Direct to consumer advertising and prescription choice. Journal of Industrial Economics 2007, 55(4):771.
59. Jayadev, A. & Stiglitz, J. (2008). Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Affairs.
60. Jena, A. & Philipson, T. (2009). Endogenous cost-effectiveness analysis in health care technology adoption. National Bureau of Economic Research Working Paper Series No. 15032.
61. Jena A.B., Philipson T. Cost-effectiveness as a price control. Health Affairs (Millwood) 2007, 26(3):696-703.
62. Jena A.B., Philipson T.J. Cost-effectiveness analysis and innovation. Journal of Health Economics 2008, 27(5):1224-1236.
63. Jena A.B., et al. Me-too innovation in pharmaceutical markets. Forum for Health Economics and Policy 2009, 12(1).
64. Klemperer P. How broad should the scope of patent protection be?. RAND Journal of Economics 1990, 21:113-130.
65. Kremer M. Patent buyouts: A mechanism for encouraging innovation. Quarterly Journal of Economics 1998, 113(4):1137-1167.
66. Kremer, M. (2000a). Creating markets for new vaccines. Part I: Rationale. National Bureau of Economic Research, Inc., NBER Working Papers.
67. Kremer, M. (2000b). Creating markets for new vaccines. Part II: Design issues. National Bureau of Economic Research, Inc., NBER Working Papers.
68. Kremer M., Snyder C. Why is there no AIDS vaccine? 2006, Harvard University, Cambridge, MA, (Harvard University Working Paper).
69. Kremer M., Williams H. Incentivizing innovation: Adding to the tool kit. Innovation Policy and the Economy 2010, 10(1):1-17.
70. Kyle M., McGahan A. Investments in pharmaceuticals before and after TRIPS 2009, National Bureau of Economic Research, Cambridge, MA, (National Bureau of Economic Research Working Paper 15468).
71. Lakdawalla D., Sood N. Health insurance as a two-part pricing contract 2006, National Bureau of Economic Research, Cambridge, MA, (National Bureau of Economic Research Working Paper 12681).
72. Lakdawalla, D. & Yin, W. (2009). Insurer bargaining and negotiated drug prices in Medicare Part D. National Bureau of Economic Research, Inc., NBER Working Papers: 15330.
73. Lakdawalla, D. N. & Philipson, T. J. (forthcoming). Intellectual property and marketing in the pharmaceutical industry. Journal of Law and Economics.
74. Lakdawalla D.N., Sood N. Social insurance and the design of innovation incentives. Economics Letters 2004, 85(1):57-61.
75. Lakdawalla D.N., Sood N. Innovation and the welfare effects of public drug insurance. Journal of Public Economics 2009, 93:541-548.
76. Lee J. How KSR broadens (without lowering) the evidentiary standard of nonobviousness. Berkeley Technology Law Journal 2008, 23(1):15-46.
77. Lee T., Wilde L.L. Market structure and innovation: A reformulation. Quarterly Journal of Economics 1980, 94(2):429-436.
78. Leffler K.B. Persuasion or information? The economics of prescription drug advertising. Journal of Law and Economics 1981, 24(1):45-74.
79. Lemley M.A., Shapiro C. Probabilistic patents. Journal of Economic Perspectives 2005, 19(2):75-98.
80. Lerner, J. & Tirole, J. (2009). Some simple economics of open source: Elgar Reference Collection. International Library of Critical Writings in Economics, vol. 241. Cheltenham, UK and Northampton, MA: Elgar.
81. Lichtenberg F.R., Waldfogel J. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act 2003, National Bureau of Economic Research, Cambridge, MA, (National Bureau of Economic Research Working Paper Entry 9750).
82. Llobet G., Hopenhayn H., Mitchell M. Rewarding sequential innovators: Prizes, patents and buyouts 2000, Federal Reserve Bank of Minneapolis, Minneapolis, MN, (Federal Reserve Bank of Minneapolis Staff Report 273).
83. Loury G.C. Market structure and innovation. Quarterly Journal of Economics 1979, 93(3):395-410.
84. Mansfield E. Patents and innovation: An empirical study. Management Science 1986, 32(2):173-181.
85. Mansfield E. The R&D tax credit and other technology policy issues. American Economic Review 1986, 76(2):190-194.
86. Martikainen J., Kivi I., Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals-a pilot study. Health Policy 2005, 75(3):235-246.
87. McCutchen W.W. Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industry. Research Policy 1993, 22(4):337-351.
88. Menell P.S., Scotchmer S. Intellectual property law. Handbook of law and economics 2007, vol. 2:1473-1570. Elsevier, New York.
89. Meurer, M. J. (2003). Pharmacogenomics, genetic tests, and patent-based incentives. Advances in Genetics, 50: 399-426; discussion 507-510, 399-426; discussion 507-510.
90. Middleton B. Achieving U.S. health information technology adoption: The need for a third hand. Health Affairs 2005, 24(5):1269-1272.
91. Mossinghoff G.J. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food & Drug LJ 1999, 54:187.
92. Nelson R.R., Winter S.G. An evolutionary theory of economic change 1982, Belknap Press of Harvard University Press, Cambridge, MA.
93. Nordhaus W.D. An economic theory of technological change. American Economic Review 1969, 59(2):18-28.
94. Nordhaus W.D. Schumpeterian profits in the American economy: Theory and measurement 2004, National Bureau of Economic Research, Cambridge, MA, (National Bureau of Economic Research Working Paper 10433).
95. O'Donoghue T., Scotchmer S., Thisse J.-F. Patent breadth, patent life, and the pace of technological progress. Journal of Economics and Management Strategy 1998, 7(1):1-32.
96. Oi W.Y. A Disneyland dilemma: Two-part tariffs for a Mickey Mouse monopoly. Quarterly Journal of Economics 1971, 85:77-96.
97. Pauly M.V. Is it time to reexamine the patent system's role in spending growth?. Health Affairs 2009, 28(5):1466-1474.
98. Pavcnik N. Do pharmaceutical prices respond to potentional out-of-pocket expenses?. RAND Journal of Economics 2002, 33(3):469-487.
99. Pekurinen, M. & Hakkinen, U. (2005). Regulating pharmaceutical markets in Finland. STAKES. Julkaisut.
100. Philipson, T. & Mechoulan, S. (2003). Intellectual property & external consumption effects: generalizations from pharmaceutical markets. National Bureau of Economic Research Working Paper Series No. 9598.
101. Philipson T.J., Jena A.B. Surplus appropriation from R&D and health care technology assessment procedures 2006, National Bureau of Economic Research, Cambridge, MA, (National Bureau of Economic Research Working Paper 12016).
102. Ridley D.B., Grabowski H.G., Moe J.L. Developing drugs for developing countries. Health Affairs 2006, 25(2):313-324.
103. Roberts E.B. Technological innovation and medical devices 2003, Massachusetts Institute of Technology (MIT), Sloan School of Management, Cambridge, MA, (Massachusetts Institute of Technology (MIT), Sloan School of Management Working Paper 1930-87).
104. Rosenfeld S., Bernasek C., Mendelson D. Medicare's next voyage: Encouraging physicians to adopt health information technology. Health Affairs 2005, 24(5):1138-1146.
105. Rosenthal M.B., et al. Promotion of prescription drugs to consumers. New England Journal of Medicine 2002, 346(7):498-505.
106. Rosenthal M.B., et al. Demand effects of recent changes in prescription drug promotion. Frontiers in Health Policy Research 2003, 6:1-26.
107. Roth M.S. Patterns in direct-to-consumer prescription drug print advertising and their public policy implications. Journal of Public Policy & Marketing 1996, 15(1):63-75.
108. Sanjuan J. U.S. and E.U. protection of pharmaceutical test data. Consumer project on technology 2006, Consumer Project on Technology, Washington, DC.
109. Scherer F.M. The link between gross profitability and pharmaceutical R&D spending. Health Affairs 2001, 20(5):216-220.
110. Scotchmer S. On the optimality of the patent renewal system. RAND Journal of Economics 1999, 30(2):181-196.
111. Scotchmer S., Green J. Novelty and disclosure in patent law. RAND Journal of Economics 1990, 21(1):131-146.
112. Shortliffe E.H. Strategic action in health information technology: Why the obvious has taken so long. Health Affairs 2005, 24(5):1222-1233.
113. Sood N., et al. The effect of regulation on pharmaceutical revenues: Experience in nineteen countries. Health Affairs (Millwood) 2009, 28(1):w125-w137.
114. Telser L.G. Advertising and competition. Journal of Political Economy 1964, 72(6):537-562.
115. Thamer M., Brennan N., Semansky R. A cross-national comparison of orphan drug policies: Implications for the U.S. Orphan Drug Act. Journal of Health Politics, Policy and Law 1998, 23(2):265-290.
116. Toole A.A. Does public scientific research complement private investment in research and development in the pharmaceutical industry?. Journal of Law and Economics 2007, 50(1):81-104.
117. US Department of Commerce Pharmaceutical price controls in OECD Countries: Implications for U.S. consumers, pricing, research and development, and innovation 2004, ITA US Department of Commerce, Washington, DC.
118. Vernon J.A. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 2005, 14(1):1-16.
119. Ward M.R., Dranove D. The vertical chain of research and development in the pharmaceutical industry. Economic Inquiry 1995, 33(1):70-87.
120. Weisbrod B.A. The health care quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. Journal of Economic Literature 1991, 29(2):523-552.
121. Williams H. Intellectual property rights and innovation: Evidence from the Human Genome 2010, Dissertation, Harvard University, Department of Economics, Cambridge, MA.
122. Yin W. Market incentives and pharmaceutical innovation. Journal of Health Economics 2008, 27(4):1060-1077.